Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) shares rose 2.3% during trading on Friday . The company traded as high as $14.85 and last traded at $14.83, with a volume of 253,073 shares trading hands. The stock had previously closed at $14.49.

LXRX has been the topic of a number of research analyst reports. Wedbush increased their target price on Lexicon Pharmaceuticals from $28.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, May 31st. Needham & Company LLC reissued a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a research note on Wednesday, May 4th. Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. Cowen and Company reissued a “market perform” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, May 3rd. Finally, JPMorgan Chase & Co. restated a “hold” rating and set a $16.00 price target on shares of Lexicon Pharmaceuticals in a research report on Thursday, May 5th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. Lexicon Pharmaceuticals currently has an average rating of “Hold” and an average price target of $18.50.

The firm has a 50 day moving average price of $14.26 and a 200-day moving average price of $12.28. The stock’s market capitalization is $1.56 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter last year, the business posted ($0.04) EPS. The business’s quarterly revenue was up 594.4% compared to the same quarter last year. Equities research analysts predict that Lexicon Pharmaceuticals Inc. will post ($1.55) EPS for the current year.

In related news, VP James F. Tessmer sold 6,000 shares of Lexicon Pharmaceuticals stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $78,000.00. Following the transaction, the vice president now owns 21,946 shares in the company, valued at approximately $285,298. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Several hedge funds and institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its position in Lexicon Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 76,947 shares of the biopharmaceutical company’s stock worth $1,024,000 after buying an additional 1,372 shares during the period. ProShare Advisors LLC boosted its position in Lexicon Pharmaceuticals by 7.7% in the fourth quarter. ProShare Advisors LLC now owns 89,382 shares of the biopharmaceutical company’s stock worth $1,190,000 after buying an additional 6,390 shares during the period. Nationwide Fund Advisors boosted its position in Lexicon Pharmaceuticals by 124.1% in the fourth quarter. Nationwide Fund Advisors now owns 139,876 shares of the biopharmaceutical company’s stock worth $1,862,000 after buying an additional 77,446 shares during the period. Finally, New York State Common Retirement Fund boosted its position in Lexicon Pharmaceuticals by 240.2% in the fourth quarter. New York State Common Retirement Fund now owns 177,168 shares of the biopharmaceutical company’s stock worth $2,358,000 after buying an additional 125,083 shares during the period.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.